UNSPSC 51351904: Gestrinone

This classification denotes a therapeutic progestin with the molecular formula C21H24O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1421533RCM, chemically known as 18,19-dinorpregna-4,9,11-trien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)- (9ci) but generally known as gestrinone, which bears US NIH Compound Identifier 27812. European Medicines Agency schedules Gestrinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13963MIG. The term GESTRINONE is an International Non-Proprietary Name.

UNSPSC 51351904 Gestrinone, a Commodity code, encompasses pharmaceutical products that state and local government health agencies, cooperative purchasing alliances, and procurement offices acquire through multistate frameworks and direct contracts. The code covers branded and generic pharmaceutical formulations supplied through authorized wholesaler networks to support public health facilities, correctional institutions, and social service agencies. State and local buyers under this code operate primarily through cooperative purchasing vehicles like multistate alliances rather than individual jurisdictional procurements, reflecting the complexity of pharmaceutical supply-chain management, FDA compliance, pricing negotiation, and authorized-wholesaler relationships.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (RFP S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Awarded vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and meet cGMP and Drug Supply Chain Security Act (DSCSA) compliance requirements, maintain contractual relationships with at least two of the three wholesalers, and carry comprehensive insurance including $5,000,000 in commercial general liability coverage. The evaluation heavily weights price competitiveness (75 percent) alongside compliance, EDI capability, fixed pricing, and administrative-fee agreement, with the contract term set at two years for new vendors and extensions at MMCAP's discretion through June 30, 2028 for incumbents.